

Clinical Trial Development of Small Molecule Inhibitor for Progeria Treatment: Progerinin

PRG S&Tech Inc.



OTHERS	Phase 2
Product Type	Small-molecule (Rare Pediatric Drug)
Indication	<ul style="list-style-type: none"> • Hutchinson-Gilford Progeria Syndrome (“Progeria” or “HGPS”) • Werner Syndrome
Target	Progerin protein and Lamin A binding
MoA(Mechanism of Action)	Progerin protein and Lamin A binding inhibitor
Competitiveness	<ul style="list-style-type: none"> • First-in-class drug • ODD, RPDD Approval from FDA and OMPD Approval From EMA
Development Stage	Phase 2
Route of Administration	Oral